Search company, investor...

IDEC Pharmaceuticals

idecpharm.com

Stage

Merger | Merged

Valuation

$0000 

About IDEC Pharmaceuticals

Producer of antibody-based treatment for lymphoma. The company completed an IPO and later merged with Biogen (Nasdaq: BIIB).

Headquarters Location

Corporate Headquarters 14 Cambridge Center

Cambridge, Massachusetts, 02142,

United States

Missing: IDEC Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: IDEC Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest IDEC Pharmaceuticals News

Deal of the (last) century set to bear fruit for Biogen once again

Dec 19, 2022

1995 was a good year in licensing for Massachusetts-based biotech pioneer Biogen (Nasdaq: BIIB). It was then that the formerly independent Idec Pharmaceuticals agreed terms for a discovery collab in the area of anti-CD20 antibodies with Genentech, part of Swiss cancer giant Roche (ROG: SIX). Over the years, the agreement has yielded significant revenues from the USA’s first approved radioimmunotherapy, Zevalin (ibritumomab tiuxetan), not to mention… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

IDEC Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is IDEC Pharmaceuticals's headquarters?

    IDEC Pharmaceuticals's headquarters is located at Corporate Headquarters, Cambridge.

  • What is IDEC Pharmaceuticals's latest funding round?

    IDEC Pharmaceuticals's latest funding round is Merger.

  • Who are the investors of IDEC Pharmaceuticals?

    Investors of IDEC Pharmaceuticals include Biogen IDEC, SR One, Abingworth, Kleiner Perkins Caufield & Byers, Alloy Ventures and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.